Study Explores MET Inhibitors with Chemoimmunotherapy to Address Resistance in Small Cell Lung Cancer

A recent study has provided evidence supporting the use of MET inhibitors in combination with chemoimmunotherapy as a potential treatment strategy for certain patients with small cell lung cancer (SCLC). The findings, based on both preclinical and translational research, suggest that this approach may help overcome treatment resistance in some cases.

The research highlights MET inhibition as a viable therapeutic target for SCLC. Preclinical studies demonstrated the role of MET signaling in driving tumor progression and resistance to standard treatments. Translational evidence further supported these findings by showing that combining MET inhibitors with chemoimmunotherapy could enhance treatment efficacy. These results indicate that targeting the MET pathway may offer new options for patients who have limited responses to existing therapies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 20, 2025

Author

Mark Chiang